Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Doxorubicin, Ifosfamide, Radiotherapy, and Surgery for Retroperitoneal Sarcoma
NCT00017160Phase 2Withdrawn
- Sponsor
- NRG Oncology
- Modality
- DNA Intercalators/Alkylators
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin and ifosfamide in retroperitoneal sarcoma (RPS), sponsored by NRG Oncology. Primary endpoint: Overall Survival. Status: withdrawn.
02
Drugs
doxorubicinifosfamide
03
Conditions
retroperitoneal sarcoma (RPS)
Beyond the preview
Go deeper on NCT00017160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00017160.